These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

214 related articles for article (PubMed ID: 26277199)

  • 1. Novel therapies for osteoporosis.
    Makras P; Delaroudis S; Anastasilakis AD
    Metabolism; 2015 Oct; 64(10):1199-214. PubMed ID: 26277199
    [TBL] [Abstract][Full Text] [Related]  

  • 2. New treatment modalities in osteoporosis.
    Canalis E
    Endocr Pract; 2010; 16(5):855-63. PubMed ID: 20350910
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effects of denosumab on bone mineral density and bone turnover in postmenopausal women.
    Wensel TM; Iranikhah MM; Wilborn TW
    Pharmacotherapy; 2011 May; 31(5):510-23. PubMed ID: 21923432
    [TBL] [Abstract][Full Text] [Related]  

  • 4. New developments in the treatment of osteoporosis.
    Eriksen EF; Halse J; Moen MH
    Acta Obstet Gynecol Scand; 2013 Jun; 92(6):620-36. PubMed ID: 22646526
    [TBL] [Abstract][Full Text] [Related]  

  • 5. New therapeutic targets for osteoporosis: beyond denosumab.
    Lim V; Clarke BL
    Maturitas; 2012 Nov; 73(3):269-72. PubMed ID: 22925430
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Latest innovation in the treatment of osteoporosis: SERMs and the role of parathyroid hormone.
    Thiebaud D
    J Med Assoc Thai; 2004 Oct; 87 Suppl 3():S124-5. PubMed ID: 21213508
    [No Abstract]   [Full Text] [Related]  

  • 7. [Trends in osteoporosis].
    Uebelhart B; Rizzoli R
    Rev Med Suisse; 2008 Jan; 4(140):144-6, 148-9. PubMed ID: 18309878
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Role of RANK ligand and denosumab, a targeted RANK ligand inhibitor, in bone health and osteoporosis: a review of preclinical and clinical data.
    Dempster DW; Lambing CL; Kostenuik PJ; Grauer A
    Clin Ther; 2012 Mar; 34(3):521-36. PubMed ID: 22440513
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacological diversity among drugs that inhibit bone resorption.
    Russell RG
    Curr Opin Pharmacol; 2015 Jun; 22():115-30. PubMed ID: 26048735
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Selective estrogen receptor modulators: A possible new treatment of osteoporosis in males.
    Kastelan D; Giljevic Z; Kraljevic I; Korsic M
    Med Hypotheses; 2006; 67(5):1052-3. PubMed ID: 16790322
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Sclerostin and DKK1 in postmenopausal osteoporosis treated with denosumab.
    Gatti D; Viapiana O; Fracassi E; Idolazzi L; Dartizio C; Povino MR; Adami S; Rossini M
    J Bone Miner Res; 2012 Nov; 27(11):2259-63. PubMed ID: 22692843
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Effect on bone structure and strength by novel anti-osteoporotic agents].
    Sone T
    Clin Calcium; 2013 Jul; 23(7):1021-6. PubMed ID: 23811591
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Bone remodeling: new therapeutic approaches].
    Ferrari S
    Rev Med Suisse; 2009 Jun; 5(207):1325-8. PubMed ID: 19626933
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Osteoporosis].
    Uebelhart B; Ferrari S
    Rev Med Suisse; 2017 Jan; 13(544-545):88-90. PubMed ID: 28703545
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Similar relationship between the time course of bone mineral density improvement and vertebral fracture risk reduction with denosumab treatment in postmenopausal osteoporosis and prostate cancer patients on androgen deprivation therapy.
    Pérez Ruixo JJ; Zheng J; Mandema JW
    J Clin Pharmacol; 2014 May; 54(5):503-12. PubMed ID: 24214315
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Time course of bone mineral density changes with denosumab compared with other drugs in postmenopausal osteoporosis: a dose-response-based meta-analysis.
    Mandema JW; Zheng J; Libanati C; Perez Ruixo JJ
    J Clin Endocrinol Metab; 2014 Oct; 99(10):3746-55. PubMed ID: 24915115
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy and safety of bazedoxifene, a novel selective estrogen receptor modulator for the prevention and treatment of postmenopausal osteoporosis.
    Palacios S
    Curr Med Res Opin; 2010 Jul; 26(7):1553-63. PubMed ID: 20429824
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Randomised controlled study of effect of parathyroid hormone on vertebral-bone mass and fracture incidence among postmenopausal women on oestrogen with osteoporosis.
    Lindsay R; Nieves J; Formica C; Henneman E; Woelfert L; Shen V; Dempster D; Cosman F
    Lancet; 1997 Aug; 350(9077):550-5. PubMed ID: 9284777
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Recent advances in the management of osteoporosis.
    Fukumoto S; Matsumoto T
    F1000Res; 2017; 6():625. PubMed ID: 28529724
    [TBL] [Abstract][Full Text] [Related]  

  • 20. New approaches to the treatment of osteoporosis.
    Silva BC; Bilezikian JP
    Annu Rev Med; 2011; 62():307-22. PubMed ID: 21054170
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.